The FDA Approval of Regeneron's EYLEA Is Important
The PANORAMA Trial of EYLEA for Diabetic Retinopathy
The United States Food and Drug Administration (FDA) has approved Regeneron’s (REGN) product EYLEA® (aflibercept) Injection for all stages of diabetic retinopathy. This approval is important. The data demonstrated from the PANORAMA trial showed EYLEA’s . . .
This content is for paid subscribers.
Today’s Highlights
May 14, 2019
